CRYOSTEM builds strong partnerships with academic and industrial playersTo develop innovative biobanking solutions
Ancillary studies, multi-disciplinary approaches, biobanking and biocollection structures, CRYOSTEM at the heart of innovative health projects.
CRYO-LEA Biological Resources Collection
Enrichment of the L.E.A (Childhood and Adolescent Leukemia) cohort by the constitution of biological resources collection from blood or skin samples taken from patients treated respectively with chemotherapy (75%) or bone marrow transplant (25%) for childhood leukemia.
→ To identify predictive factors of long-term sequelae of chemotherapy or bone marrow transplant treatments in children with leukemia (GEN-LEA program).
→ To offer personalized therapeutics
→ To improve patients quality of life
CRYO-LEA in figures* :
→ Number of patients included: 1 899
→ Number of samples available: 15 512
→ Number of partnering centers: 16
* as of 10/31/2021
Partner : L.E.A., prospective multicentric cohort of Child and Adolescent Leukemias
Investigators : Professeurs Gérard Michel, service pédiatrie et oncologie pédiatrique (Hôpital de la Timone) – Pascal Auquier, Faculté des Sciences Médicales et Paramédicales, UR3279 CERESS (Centre d’Etudes et de Recherches sur les Services de Santé et qualité de vie)
Promotor : Assistance Publique – Hôpitaux de Marseille (AP-HM)
Ancillary study of the Mac-Haplo-Mud clinical protocol
The purpose of the ancillary study is to build a biological resources collection from transplant patients included in the prospective randomized Phase III Mac-Haplo-Mud clinical trial.
The Mac-Haplo-Mud clinical protocol aims to compare haplo-identical* (half-compatible family donor with the patient for HLA genes) and pheno-identical (100% compatible family donor) grafts after reduced conditioning.
* The results of haplo-identical transplants with injection of a drug, Endoxan, are currently comparable in terms of overall survival and disease-free survival to transplants from an unrelated HLA-matched donor, but with less toxicity, including reduced rates of graft-versus-host disease (retrospective studies).
Mac-Haplo-Mud in figures* :
→ Number of patients included: 75
→ Number of samples taken: 163
→ Number of samples available: 489
→ Number of partnering centers: 20 (open to collection)
* as of 30/09/2021
Project coordinators : Pr Régis Peffault de Latour, Service d’Hématologie Greffe Hôpital Saint-Louis, Paris, Pr Marie-Thérèse Rubio, Service d’Hématologie du CHU Nancy
Promotor : Assistance Publique – Hôpitaux de Paris (AP-HP)
CeVi_CAR-T Biological Resources Collection
Creation of a perfectly annotated biological resources collection from blood samples of lymphoma patients treated with CAR-T cells. This collection, initiated in January 2020, is complementary to the lymph node samples provided by members of the CALYM network.
To provide teams with the necessary material to develop ambitious research programs consistent with the state of the art in order to respond to current issues:
→ To better identify and understand the biological mechanisms at the origin of CAR-T cell efficacy, but also of resistance to CAR-T cell treatments.
→ To have the epidemiological, clinical and biological information needed to optimize CAR-T strategies.
CeVi_CAR-T in figures*:
→ Number of partnering centers: 5
→ Number of patients included: 115
* as of 05/31/2021
Partner : The objective of the Institut Carnot CALYM is to promote innovation in lymphoma research and accelerate its transfer to the clinic and the health industry through public/private partnerships. The Carnot CALYM Institute coordinates and funds the CeVi_CART-T collection: a unique, perfectly annotated collection of cryopreserved viable human cells from lymphomas and reactive lymphoid tissues that federates 6 CALYM research units and their BRCs.
Constitution of a prospective cohort of patients receiving an allogeneic hematopoietic stem cell transplant
Evaluate the levels of biomarkers in the blood of patients at risk of transplant rejection or developing acute graft-versus-host disease after allogeneic transplant of hematopoietic stem cells or with pre-transplant deficits of hematopoietic stem cell proliferation.
→ Establish a prospective cohort of patients receiving an allogeneic hematopoietic stem cell transplant and presenting post-transplant complications such as transplant rejection or acute graft-versus-host disease.
→ Establish a prospective cohort of patients with pre-transplant proliferation deficits of hematopoietic stem cells.
→ Validate the possibility of using predictive biomarkers of post-transplant complications with the objective to establish diagnostic test(s).
→ Study the relationship between certain biological mechanisms and stem cell proliferation deficits.
→ Validate the scientific rationale to establish new clinical protocols to test the potential of new treatment(s) for post-transplant complications such as prevention of transplant rejection, treating graft-versus-host disease or stem cell proliferation deficits.
The NI-0501-13 study in figures:
→ Total number of patients planned: 250
→ Number of partner centers in France: 12
Project leader, promoter and partner: Swedish Orphan Biovitrum (Sobi)
Investigators: CHU Angers, Hôpital universitaire Robert-Debré – AP-HP, Hôpital Saint-Louis – AP-HP, CHU Bordeaux, CHU Rennes, CHU Nancy, CHU Grenoble, CHU Clermont-Ferrand, CHU Montpellier (adult and pediatric units), CHU Caen, CHU Besançon.